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Background: Tremendous research from last twenty years has been pursued to cure human life against HIV virus. A
large number of HIV protease inhibitors are in clinical trials but still it is an interesting target for researchers due to
the viral ability to get mutated. Mutated viral strains led the drug ineffective but still used to increase the life span
of HIV patients.
Results: In the present work, 3D-QSAR and docking studies were performed on a series of Danuravir derivatives,
the most potent HIV- protease inhibitor known so far. Combined study of 3D-QSAR was applied for Danuravir
derivatives using ligand-based and receptor-based protocols and generated models were compared. The results
were in good agreement with the experimental results. Additionally, docking analysis of most active 32 and least
active 46 compounds into wild type and mutated protein structures further verified our results. The 3D-QSAR and
docking results revealed that compound 32 bind efficiently to the wild and mutated protein whereas, sufficient
interactions were lost in compound 46.
Conclusion: The combination of two computational techniques would helped to make a clear decision that
compound 32 with well inhibitory activity bind more efficiently within the binding pocket even in case of mutant
virus whereas compound 46 lost its interactions on mutation and marked as least active compound of the series.
This is all due to the presence or absence of substituents on core structure, evaluated by 3D-QSAR studies. This set
of information could be used to design highly potent drug candidates for both wild and mutated form of viruses.
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Human immunodeficiency virus (HIV) is a retrovirus
that is peril to human health, responsible to cause AIDS,
an immunodeficiency syndrome. The disease presents a
serious health care challenge because each year it affects
an increasing number of people across the globe [1]. To
combat disease, several new drugs were approved by
FDA which reduces the morbidity and mortality of HIV
infection. These drugs are categorized as HIV-Reverse
transcriptase (HIV-RT), HIV-Integrase (HIN-IN) &
HIV-Protease inhibitors (HIV-PIs), the major targeted
enzymes of HIV life cycle. HAART (highly active anti-
retroviral therapy) is the most promising anti-AIDS ther-
apy including these inhibitors in combination. The
major obstacle in the use of HAART therapy is* Correspondence: zaheer.qasmi@iccs.edu
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reproduction in any medium, provided the orresistance that virus develops [2]. The hyper-mutability
of HIV, drug resistance and their side effects are the big-
gest challenge to develop an effective anti-AIDS therapy.
HIV-1 Protease is emerging as one of the major
druggable target for the development of new chemother-
apeutics. HIV protease inhibitors, restrain the viral mat-
uration by preventing the formation of structural and
functional proteins and form immature, non-infectious
virus. However, it is highly prone to develop mutations,
since it is a homodimer and a single mutation of gene
causes double mutation of enzyme [3]. Structurally, HIV
protease is a homodimer protein, containing 99 amino
acids in each chain, with an active site located at the
dimer interface [4]. The protein is composed of three re-
gions; catalytic core (Asp25, Gly27, Ala28, Asp29 and
Asp30), flap (Ile47, Gly48, Gly49, and Ile50) and the C-
terminal region (Pro81, and Ile84). From literature,
Asp25, Gly27, Ala28, Asp29 and Gly49 are known to be
highly conserved residues to which a potent inhibitorral Ltd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Core structure and dataset alignment. a) Core structure of danuravir derivatives with marked points used for alignment, b) Ligand-
based alignment by using most active compound 32 as template, c) Structure-based alignment using cognate ligand of 3QOZ.pdb as reference.
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Ile50 and Ile84 (hydrophobic residues, close to binding
pocket) are responsible for the resistance to most FDA
approved drugs due to loss of Vander Waal interactions
[5]. Almost all FDA approved anti-AIDs drugs are resist-
ant to I84V mutant virus and became ineffective against
disease.
The failure of drug therapies against mutated virus pro-
tein encouraged the scientists to develop more potent, ef-
fective and stable second generation HIV-PIs, but still the
HIV-PI therapies are associated with the serious problems
that limit their significance and effectiveness [6]. In order
to take a forward step for prediction and guidance of
more effective drug, 3D-QSAR studies were conducted
as primitive step in finding new inhibitors using a dataset
of 102 (R)-hydroxyethylamino sulfonamides derivatives
from literature [7].
3D-QSAR technique is subdivided into ligand-based
and structure-based methods. Ligand-based approach is
frequently applicable in the absence of experimentally
resolved protein crystal structure whereas, structure-
based method extract the protein bound ligand informa-
tion for the generation of align model [8-10]. In the
present work, both strategies were applied to generate
the CoMFA and CoMSIA models and their comparison
with reference to the most active moiety Darunavir
(hydroxyethylamino sulfonamides derivatives). Extensive
research is ongoing that used different scaffolds, meth-
odology and algorithms for predicting better results.Darunavir (DRV) is one of the most attracting targets as
it is the most active molecule among eleven FDA ap-
proved drugs of present time [11]. The obtained models
revealed the significance of stereoelectronic properties,
hydrogen bonding characteristics and structure varia-
tions leading to changes in the interaction profile. The
influences of grid distances, alignment methods and
combination of charges were explored out of which the
best model was selected. Additionally, molecular
docking of compounds explored the binding affinity of
highly active and least active compounds with its recep-
tor by using GOLD docking suit [12]. The purpose of
the study was to validate the experimental results
obtained with Darunavir derivatives and to predict the
compound that may developed into a more potent HIV
inhibitor based on outcomes extracted from the current
study.Results and discussion
Protease active site is composed of catalytic triad having
two C2 symmetrical monomeric units, Asp25 (25')-
Thr26 (26')-Gly27 (27'). This triad is surrounded by
amino-acids, classified into S1 (1') and S2 (2') sub-sites,
which mostly include the hydrophobic amino-acids [13].
However, on ligand binding, Protease behaves as asym-
metrical monomer [14]. Darunavir, an FDA approved
drug has shown extensive hydrogen bonding with prote-
ase backbone, especially with S2 sub-site of protease,
Table 1 Ligand-based and structure-based, actual and
predicted pIC50 values of training set generated by
CoMFA model along with their residuals
Compounds pIC50 Ligand-based Structure-based
Predicted Residuals Predicted Residuals
Comp 004 6.62 6.51 -0.11 6.71 -0.09
Comp 005 6.77 7.06 0.29 7.31 -0.54
Comp 006 7.38 6.78 -0.6 6.94 0.44
Comp 007 10.08 10.37 0.29 10.09 -0.01
Comp 008 9.77 9.7 -0.07 9.83 -0.06
Comp 009 10.15 10.13 -0.02 9.95 0.20
Comp 011 6.72 6.45 -0.27 6.64 0.09
Comp 012 6.8 7 0.2 7.23 -0.43
Comp 014 9.59 10.08 0.49 9.63 -0.04
Comp 015 11.4 10.63 -0.77 10.32 1.09
Comp 016 9.08 9.26 0.18 9.23 -0.15
Comp 017 9.74 9.95 0.21 10.05 -0.31
Comp 018 10.1 10.4 0.3 10.19 -0.09
Comp 019 10.8 10.44 -0.36 10.73 0.08
Comp 020 7.53 7.92 0.38 7.82 -0.29
Comp 021 6.78 7.19 0.41 7.33 -0.55
Comp 022 9.1 9.2 0.1 9.19 -0.09
Comp 023 10.18 10.07 -0.12 9.95 0.23
Comp 025 9.46 9.82 0.36 9.82 -0.36
Comp 026 10.07 9.86 -0.21 10.36 -0.29
Comp 027 9.42 9.73 0.31 9.59 -0.17
Comp 029 10.38 10.17 -0.21 10.55 -0.16
Comp 030 10.14 10.6 0.46 10.68 -0.54
Comp 031 10.8 10.62 -0.18 10.73 0.07
Comp 032 12.1 11.345 -0.75 11.037 1.06
Comp 033 10.49 10.78 0.29 10.89 -0.40
Comp 034 11.22 11.23 0.01 11.08 0.14
Comp 035 9.63 9.47 -0.17 9.41 0.22
Comp 036 10.72 10.68 -0.04 10.17 0.55
Comp 037 9.93 9.54 -0.39 9.78 0.15
Comp 038 7.48 7.21 -0.27 7.02 0.46
Comp 040 5.97 6.36 0.39 6.44 -0.47
Comp 041 9.41 9.46 0.05 9.32 0.09
Comp 042 7.28 6.46 -0.82 6.51 0.77
Comp 043 4.88 5.526 0.65 5.396 -0.52
Comp 044 9.77 9.208 -0.56 9.026 0.74
Comp 045 6.21 6.219 0.01 6.21 0
Comp 046 4.58 5.291 0.71 5.097 -0.52
Comp 047 5.63 6.211 0.58 6.33 -0.7
Comp 048 6.29 6.138 -0.15 6.334 -0.04
Comp 049 10.03 10.297 0.27 10.11 -0.08
Comp 050 7.39 6.763 -0.63 6.65 0.74
Table 1 Ligand-based and structure-based, actual and
predicted pIC50 values of training set generated by
CoMFA model along with their residuals (Continued)
Comp 051 10.48 10.46 -0.02 10.28 0.2
Comp 052 7.3 6.22 -1.08 6.42 0.88
Comp 053 9.42 10.15 0.73 10.1 -0.68
Comp 056 7.62 6.93 -0.69 6.78 0.84
Comp 057 7.24 7.26 0.02 6.97 0.27
Comp 058 5.93 6.59 0.66 6.73 -0.80
Comp 060 6.27 6.57 0.3 6.45 -0.18
Comp 061 4.84 4.35 -0.49 4.44 0.40
Comp 063 4.91 4.58 -0.33 4.31 0.60
Comp 066 5.69 6.39 0.7 6.34 -0.65
Comp 069 4.87 5.65 0.78 5.59 -0.72
Comp 070 6.59 6.05 -0.54 6.05 0.54
Comp 071 9.62 9.56 -0.07 9.33 0.29
Comp 072 9.92 10.03 0.11 10.23 -0.30
Comp 073 8.38 8.32 -0.06 8.28 0.10
Comp 075 10.21 10.09 -0.12 9.75 0.46
Comp 077 9.85 9.94 0.09 10.04 -0.19
Comp 078 10.57 10 -0.57 9.89 0.68
Comp 079 8.84 9.33 0.49 9.38 -0.54
Comp 080 9.51 9.26 -0.25 9.44 0.07
Comp 081 9.93 10.21 0.28 10 -0.07
Comp 085 10.42 10.41 -0.01 10.47 -0.05
Comp 086 10.85 10.1 -0.75 10.16 0.69
Comp 088 10.24 10.59 0.35 11.04 -0.80
Comp 089 8.73 9.53 0.8 9.47 -0.74
Comp 091 8.61 8.74 0.13 9.19 -0.58
Comp 092 9.09 8.79 -0.3 9.04 0.05
Comp 094 10.2 9.41 -0.79 9.94 0.26
Comp 095 9.76 9.76 0 9.75 0.01
Comp 096 9.94 9.82 -0.12 9.61 0.33
Comp 098 9.68 9.54 -0.14 9.18 0.50
Comp 100 9.88 9.7 -0.18 9.78 0.10
Comp 101 9.43 9.93 0.5 10.06 -0.63
Comp 102 9.87 9.98 0.11 9.92 -0.05
Comp 104 9.15 9.2 0.05 9.65 -0.50
Comp 106 10.17 10.35 0.18 10.18 0.00
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tein [15].
In the present work, the additive model of Jorissen
R.N. et.al., [7] was further subjected to 3D-QSAR using
CoMFA & CoMSIA techniques and the generated con-
tour maps were further validated by molecular docking.
Table 2 Ligand-based and structure-based, actual and
predicted pIC50 values of test set generated by CoMFA
model along with their residuals
Compounds pIC50 Ligand-based model Structure-based model
Predicted Residuals Predicted Residuals
Comp 001 10 10.24 0.24 10.02 -0.02
Comp 002 8.42 8.87 0.45 8.92 -0.5
Comp 003 9.28 9.56 0.28 9.75 -0.47
Comp 010 9.97 10.17 0.2 10.5 -0.53
Comp 013 6.82 6.74 -0.08 6.89 -0.07
Comp 024 9.64 9.39 -0.25 9.69 -0.05
Comp 028 11.22 10.74 -0.48 10.69 0.53
Comp 039 10.34 10.57 0.23 10.08 0.26
Comp 054 5.94 6.62 0.68 6.69 -0.75
Comp 055 6.23 6.44 0.21 6.76 -0.53
Comp 059 6.92 6.18 -0.75 5.98 0.94
Comp 064 5.32 4.88 -0.44 6.28 -0.96
Comp 074 8.79 8.43 -0.36 8.39 0.4
Comp 076 10.2 10.04 -0.16 10.17 0.03
Comp 082 10.44 10.27 -0.17 9.86 0.58
Comp 083 10.08 10.82 0.74 10.58 -0.5
Comp 084 10 10.87 0.87 10.44 -0.44
Comp 087 10.48 10.13 -0.35 10.14 0.34
Comp 090 9.54 9.58 0.04 9.33 0.21
Comp 093 9.21 8.95 -0.26 9.03 0.18
Comp 097 9.1 9.65 0.55 9.12 -0.02
Comp 099 9.68 9.39 -0.29 9.04 0.64
Comp 103 9.07 9.26 0.19 9.35 -0.28
Comp 105 9.47 10.3 0.83 10.31 -0.84
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The reliability of CoMFA and CoMSIA models were
highly dependent on the better alignment of molecules
in a three dimensional space. The database alignment
implemented in Sybyl7.3 [16] was used to align 102
compounds using most active compound 32 as a tem-
plate. The core structure of compound 32 was chosen as
a structural element for superimposition of all other
compounds (Figure 1a). The alignment is shown in
Figure 1b and c. The statistical model of training and
test tests (Tables 1 and 2) generated for the initial data
set was depicted in Table 3. From the results, it can be
deduced that lowering the grid space showed negative
impact on the model. The default value of the grid space
was selected as best and was used for further studies. To
validate the model by external test set, activities of 24
compounds were predicted and the residual values for
external and internal data sets were evaluated (Table 2).
The best model with convincing statistical results is
shown in Table 3 and the residual value for the bestmodel was found to be less than 1 in both training and
test sets as mentioned in Tables 1 and 2. Furthermore
CoMSIA was applied on the same dataset and the re-
sults are tabulated in Table 4.
Statistics of the receptor based models
In ligand-based approach, several combinations of
charges and grid spacing were used. Among them, the
model generated by using MMFF94 charges was re-
trieved as the best model with q2 value of 0.74, standard
error of prediction was 0.99 and the r2 value of 0.96.
The results are summarized in Table 4. For structure-
based method, the bound conformation of Darunavir in
the crystal structure of HIV protease (PDB: 3QOZ)
[17,18] was used as a template to align the series of 102
compounds (Figure 1c). As shown in Table 1, the
structure-based QSAR method returned with the q2
value of 0.682, r2 of 0.938, F value of 178.46 and lower
standard error of estimate and standard error of predic-
tion with an average residual values of 0.077. While the
r2 value of the test set was 0.947. This statistical evalu-
ation showed that the performance of the structure-
based method was comparable to the ligand-based
approach for CoMFA studies (Table 3).
In CoMSIA, cross validated value of 0.664 and 0.751
was obtained for the structure-based and ligand-based
methods, respectively. The CoMSIA analysis is tabulated
in Table 4. Similarly, predictive r2 value was 0.927 and
0.929 for structure-based and ligand-based methods,
respectively.
Contour maps of CoMFA
CoMFA contours of different colors represented differ-
ent fields i.e. steric (bulky favored- green whereas yellow
is indicative of bulky disfavored area). Similarly, blue
and red regions described electron donating and
accepting groups would be favored or disfavored,
respectively.
Figure 2a and 2c displayed CoMFA generated steric
and electrostatic contour maps for ligand-based and
structure-based models, respectively. The most active
compound 32 was superimposed on the steric and elec-
trostatic contours maps for clear illustration.
The analysis of contour maps generated by ligand and
structure-based methods showed that the electronegativ-
ity (red polyhedral) is favored at R1 position in com-
pound 32 where 3-phenyloxaolidin-2-one ring is present.
While, the presence of prop-1-ene group at this position
in compound 46 has a negative effect on the biological
activity depicted in Figure 2b (ligand-based) and 2d
(structure-based). Similarly, electropositivity (blue con-
tours) is favored between benzene ring and nitrogen of
3-phenyloxaolidin-2-one in compound 32. The increase
or decrease in electronegativity, represented by red
Table 3 The statistics of all generated CoMFA models in order to obtained the best model
Charges Model GS q2 SEP C r2 SEE F r2pred
Ligand-Based Method
Gasteiger Huckel First 0.5 0.77 0.9 6 0.93 0.45 171.85 0.91
1 0.77 0.9 6 0.93 0.47 173.31 0.91
1.5 0.74 0.95 6 0.95 0.49 179.4 0.91
2 0.73 0.92 5 0.92 0.5 181.12 0.91
Best 2 0.71 1.03 6 0.94 0.44 212.63 0.96
AM1BCC First 0.5 0.65 1.12 6 0.9 0.56 117.99 0.87
1 0.64 1.13 6 0.9 0.56 118.9 0.88
1.5 0.64 0.96 6 0.94 0.57 116.85 0.88
2 0.74 1.01 6 0.93 0.42 217.07 0.9
Best 2 0.72 0.94 6 0.92 0.49 173.85 0.9
MMFF94 First 0.5 0.74 0.94 5 0.92 0.51 175.71 0.92
1 0.74 0.95 5 0.92 0.51 176.35 0.91
1.5 0.72 0.98 5 0.92 0.51 172.22 0.91
2 0.78 0.88 5 0.95 0.39 263.64 0.93
Best 2 0.74 0.99 6 0.95 0.42 240.75 0.96
Structure-Based Method
MMFF94 Best 2 0.682 1.09 6 0.93 0.48 178.46 0.93
Where: GS grid spacing, q2: cross validated correlation coefficient, SEP Standard Error of Prediction, C optimal number of Components, r2: non-cross validated
correlation coefficient, SEE Standard Error of Estimation, F Fischer test values, r2pred : prediction of external test set for validation.
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activities. If we compared compounds 28–31 with 7–14,
it was found that they have huge difference in their in-
hibitory activity due to the difference in number of elec-
tronegative fluorine at R1 position which buried near red
isopleth. Even the compounds having propanone moiety
at same position, more declined activity was observed.
Second red polyhedral was observed near R2 position,
surrounded the isobutane moiety of compound 32,
which demonstrated that the substitution of electronega-
tive element at this position could further enhance the
biological activity of the compound 32.
At R2 position, less bulky group would be favorable for
biological activity, indicated by yellow polyhedral. Com-
pounds 4, 6, 21 and 55 contained bulky group at this
position and considered as less effective with inhibitory
activity as compared to active. Similarly, comparison of
compound 43 with template 32, it was revealed that re-
placement of 2-methyl thiophene with less bulky sub-
stituent at R2 position would help to enhance its
inhibitory activity. A large green polyhedral found near
R3 position indicating if replaced anisole moiety of com-
pound 32 with more bulkier group would be beneficial
for better activity.
Presence of methoxy phenyl at para position of com-
pound 32, strongly favored the inhibitory activity as elec-
tronegative and bulky group is required at R3 position.Compounds which pose methoxy phenyl group at this
position, showed activity not less than 8.38. While com-
pounds 43 and 46 contained isoxazole group at this pos-
ition, could be the reason of their reduced activity.
Contour maps of CoMSIA
The CoMSIA steric and electrostatic descriptors were
found to be identical with the CoMFA generated models,
which proved the consistency of the results. Moreover,
the results of other three descriptors of CoMSIA also
improved the drug prediction. The hydrogen bond
donor and acceptor descriptors revealed the reason of
higher activity of compound 32. At R1 position of 32,
the purple polyhedral is surrounded which showed that
this is donor disfavored region. In compound 32,
this donor disfavored region is supplemented by the
presence of highly electronegative elements in 3-
phenyloxazolidin-2-one ring. At R2 position hydrogen
bond acceptor is disfavored (red polyhedral); at this pos-
ition an alkyl chain is present in compound 32. At R3
position a hydrogen bond acceptor is favored (magenta
polyhedral), which is supplemented by the presence of
methoxy group. In contrast, these properties are absent
in least active compound 46 which possibly the reason
of its lower activity.
The hydrophobic descriptor of CoMSIA is important
to evaluate the hydrophobicity required to sustain the
Table 4 Ligand-based and structure-based CoMSIA models along with percentage contribution of their descriptors
COMBINATIONS q2 r2 r2pred F C SEE SEP 1% 2% 3% 4% 5%
S+ES 0.714 0.927 150.91 6 0.524 1.038 37.1 62.9 _ _ _
S+H 0.728 0.935 171.61 6 0.493 1.014 42.9 57.1 _ _ _
S+D 0.681 0.89 95.284 6 0.645 1.096 62.5 37.5 _ _ _
S+A 0.756 0.941 190.33 6 0.47 0.959 55 45 _ _ _
S+D+A 0.727 0.936 171.69 6 0.493 1.015 42 34.7 23.3 _ _
ES+H 0.728 0.935 171.28 6 0.494 1.014 53.2 46.8 _ _ _
ES+D 0.69 0.912 122.84 6 0.576 1.082 70.6 29.4 _ _ _
ES+A 0.755 0.945 203.06 6 0.456 0.96 62.1 37.9 _ _ _
ES+D+A 0.713 0.938 178.42 6 0.484 1.041 50.8 28.8 20.4 _ _
H+D 0.692 0.917 130.07 6 0.561 1.078 68.2 31.8 _ _ _
H+A 0.745 0.942 193.39 6 0.466 0.98 59.7 40.3 _ _ _
H+S+ES 0.731 0.946 206.42 6 0.452 1.007 35.1 24.8 40.2 _ _
H+D+A 0.717 0.934 167.58 6 0.499 1.033 47 30.9 22.1 _ _
D+A 0.493 0.825 55.777 6 0.812 1.383 41 59 _ _ _
D+S+ES 0.707 0.932 161.84 6 0.507 1.051 23.3 27.7 49 _ _
A+S+ES 0.755 0.952 232.8 6 0.427 0.962 29.1 26.9 44 _ _
S+ES+D+A 0.732 0.948 214.79 6 0.444 1.005 21.9 37.7 22.6 17.8 _
S+H+D 0.718 0.936 173.05 6 0.491 1.032 32.7 43.8 23.5 _ _
S+H+A 0.766 0.952 234.85 6 0.425 0.939 30.2 40 29.9 _ _
ES+H+D 0.727 0.94 185.88 6 0.475 1.014 44 35 21 _ _
ES+H+A 0.761 0.953 238.73 6 0.422 0.949 40.5 33.2 26.3 _ _
H+D+S+ES 0.733 0.948 216.44 6 0.442 1.003 28 18.6 19.8 33.6 _
H+A+S+ES 0.762 0.958 272.47 6 0.396 0.948 27.2 21.5 19.5 31.8 _
S+H+D+A 0.747 0.949 220.3 6 0.438 0.977 25.1 33.6 23.5 17.8 _
ES+H+D+A 0.747 0.954 246.39 6 0.416 0.977 34.9 27.4 21.4 16.2 _
H+S+ES+D+A 0.751 0.958 0.93 270.35 6 0.398 0.97 22.8 16.5 28.2 18.1 14.4
Structure Based Model
H+S+ES+D+A 0.664 0.955 0.927 252.32 6 0.411 1.125 26.2 15.4 25.4 16.7 16.3
Where: q2: cross validated correlation coefficient, r2: non-cross validated correlation coefficient, r2pred : prediction of external test set for validation, F Fischer test
values, C optimal number of Components, SEE Standard Error of Estimation, SEP Standard Error of Prediction, %1-5: percentage contribution of descriptors in the
field, respectively, S Steric field, ES Electrostatic field, H Hydrophobic descriptor, D hydrogen bond Donor field, and A hydrogen bond Acceptor field.
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hydrophobicity is highly disfavored (white isopleth)
whereas R3 is hydrophobic favored (yellow contours) re-
gion. As shown in Figure 3c, compound 32 contained ni-
trogen containing hydrophilic moiety at R1 position
while this hydrophilic moiety is absent in compound 46
(Figure 3f ). In compound 32, the R3 position is
substituted with the phenyl-methoxy group while com-
pound 46 contained hetero-atomic methyl-isoxazole
moiety at R3 position, showed that hydrophilic substitu-
tion at R3 position would decrease the biological activity
of compound 46. The CoMSIA contour maps of com-
pound 32 and 46 with ligand-based and structure-based
approaches are presented in Figures 3 and 4,
respectively.Docking results
To validate the 3D-QSAR results, docking simulation
was performed and the most active compound 32 and
least active compound 46 was evaluated for their binding
interactions in the active site of protease and results
were compared. Initially, the performance of docking
software was tested by re-docking experiment. For this
purpose, crystal structures of two proteins with their
cognate ligands were retrieved from PDB and the cog-
nate ligands were re-docked. The results are summarized
in Table 5. The superimposed view of docked conformation
and the reference ligand is presented in Figure 5a-b.
Based on the re-docking results, GOLD was used for
docking. The comparison of the scores attributed by two
scoring functions as Gold-Score and Chem-Score also
Figure 2 CoMFA contour maps. The contour maps of CoMFA modeling, sterically favored areas are represented by green isopleths while
yellow regions are served for sterically unfavorable regions. However, electropositivity and electronegativity are represented by blue and red
contours, respectively. a-b are representative of ligand-based CoMFA descriptors of most active (comp-32) and least active (comp-46) whereas
c-d demonstrate structure-based CoMFA contour maps with active and in-active compounds, 32 and 46, respectively.
Figure 3 CoMSIA ligand-based descriptors. Representation of ligand-based CoMSIA descriptors with most active and least active compounds.
a-c depicted steric & electrostatic, acceptor & donor and hydrophobic descriptor maps of most active compound, respectively (32), whereas
d-f showed all five descriptor contours with least active compound (46).
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Figure 4 CoMSIA structure-based maps. Illustration of structure-based CoMSIA descriptors. Upper portion marked as a-c displayed steric &
electrostatic, acceptor & donor as well as hydrophobic contour maps of compound 32 claimed as most active. However, d-f are representative of
compound 46’s descriptor maps marked as least active compound within the series.
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both wild and mutated proteins. However, Gold-score
showed drastic difference between the scores of two com-
pounds which can be assumed on this basis to more ac-
curate than Chem-Score.
On the basis of docking analyses, it was revealed that
compound with highest activity (32) ranked at top pos-
ition as compared to least active compound 46. The
docking scores were in correlation with 3D-QSAR and
experimental results. The docked conformation of com-
pound 32 in wild type (Figure 6a-b) and mutated pro-
teins (Figure 6c-d) revealed that compound interacted
with the binding pocket residues of targeted proteins
through several favorable interactions including polar,
hydrophobic, hydrogen bonding and the weak Van der
Waal contacts.Table 5 Re-docking and docking results of wild type and
mutated with most active and least active compounds
PDB ID Resolution Type RMSD
3EKV 1.75 Wild 1.36
3NU9 1.85 Mutated 1.22
Docking of most and least potent compounds
Docked Comp. PDB ID Gold-Score Chem-Score
32 (Highly active) 3EKV 81.63 23.86
3NU9 72.54 22.2
46 (Least active) 3EKV 78.11 14.82
3NU9 55.68 14.1The carbonyl oxygen of the core structure near R1
position also mediated strong hydrogen bonding with
the backbone amino group of Asp29' and Asp30'. More-
over, hydrophobic interactions were observed between
Ile50 and core group of compound 32 and acetophenone
with Arg8. Pro81' also mediated hydrophobic interaction
with the methyl group of methoxybenzene present at R3
position. Furthermore side-chains of S1' residue Val82'
mediated CH--π contact with the hydrophobic portion
of the ligand at R3 position. Val32' mediated CH3–π in-
teractions with the core benzene of compound 32.
The observed docked conformation of compound 32
in the mutated protein (I84V) was flipped at ~90°,
showed in Figure 6c-d. Even with this orientation, the
ligand was found to be interacting with several import-
ant residues including Gly27, Gly27', Asp25, Asp25',
Asp29, Asp29', Ile50, GLy49' and Ile50'. In this case the
Gly27 interacted with R2 substitution and Gly27' with
core structure of compound 32. A hydrogen bond was
observed between the side chain oxygen of Asp25' and
the hydroxyl of compound 32 (2.04Å). Furthermore
Asp29' mediated a strong hydrogen bond with oxygen
atom of R1 3-phenyloxazolidin-2-one ring with the dis-
tance of 1.95Å. Moreover, the compound is stabilized by
the hydrophobic interactions offered by Ile50, Gly49'
and Ile50'. These interaction patterns of compound 32
with the wild type and mutated forms of protein sug-
gested that the modification at R2 position could in-
crease the activity of compound. This hypothesis further
confirms the results obtained by CoMFA.
Figure 5 Re-docking poses and RMSD values. Re-docking results of a) wild type (3EKV) and b) mutated (3NU9) proteins with RMSD of 1.255Å
and 1.32Å, respectively.
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http://journal.chemistrycentral.com/content/7/1/88The docked conformation of compound 46 in the wild
type protein (Figure 6e-f ) revealed that it formed CH3–π
interaction with side chain of Ile50 and Val82', however,
core benzene of compound 46 also mediated aromatic
interaction with Pro81'. On the other hand, Asp25
interacted with hydroxyl oxygen of core structure
whereas Ile50’ attracted towards oxygen of sulfonamide
near R3 substituent.
The terminal methoxy oxygen at R1 mediated interac-
tions with the wild type protein’s amino group of Asp29
and Asp30 with the distance of 2.29Å and 1.7Å, respect-
ively. The interactions of compound 46 with these resi-
dues were lost upon mutation (Figure 6g-h). The
binding orientations of compound 32 and 46 (Figure 6)Figure 6 2D and 3D docking representations. A representation of dock
with wild type and mutated HIV-protease protein via 2D and 3D represent
active site residues of wild type and mutated proteins, respectively. Similarl
pocket of wild type and mutated proteins to show how the compound 46
occurred in response to mutation.revealed that compound 32 maintained its interactions
with the active site residues in wild type as well as in
mutated protein while compound 46 lost most of its
binding interactions in mutated protein as shown in
Table 6.
Conclusion
In the present work, comparison of ligand and structure-
based 3D-QSAR using CoMFA and CoMSIA were derived
for HIV-1 protease inhibitors. The statistics of both models
were convincing and comparable. The model was signifi-
cantly favored by internal and external predictions as well as
visualization of contour maps. The effect of important struc-
tural characteristic of the potent inhibitor was predicted bying interactions and poses of most active and least active molecules
ations. a-d most active compound (32) interacted with important
y, e-h represents interactions of least active compound within binding
lost its interactions and activity due to conformational change
Table 6 Protein-ligand binding interactions with specific conserved residues
Res. Spec Compound 32 Compound 46
W.T Bonds I84V Bonds W.T Bonds I84V Bonds
Gly 27 √ HC…π √ O…HC






25' OH…O (2.04Å) √ OH…O
29 O…NH √ O…NH (2.29Å)
29' √ CO…NH (1.95Å) √
30 √ O…NH (1.75Å)
30' √ CO…NH
Val 82
82' √ CH…π √ CH…O √ CH…π √ HC…CH
32
32' √ CH…π √ CH…HC
Pro 81' √ CH…π √ C-H…O √ HC…π
Ile 50 √ CH…CH
50' √ NH…π √ CH…O
84' CH…π
Note: Distances of important interactions are shown in Å, however, all interactions mentioned here having distances of less than 3Å.
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http://journal.chemistrycentral.com/content/7/1/88the generated model. From the predictions, it was evident
that at R1 position electronegativity is favored due to pres-
ence of Asp29 in its vicinity and hydrophobicity is disfavored
which is relevant with the presence of methyloxazolidione
ring in compound 32. Docking results also showed that ter-
minal methoxy oxygen at R1 mediated bidentate interactions
with the amino group of Asp29 and Asp30 which was lost
in compound 46. At R2 position, bulkiness is disfavored
whereas at R3; hydrophobicity is favored which is evident by
presence of methoxy phenyl in compound 32. The docking
studies of most potent and least active inhibitors further
verified the generated 3D-QSAR models and can be used as
guidance for better drug development.Methodology
Dataset preparation
The dataset of 102 compounds was retrieved from lit-
erature reported by Jorissen R.N. et al., [7] and avail-
able in Additional file 1. 2D structures were drawn by
Chem-Draw [19] and converted into 3D by MOE
(Molecular Operating Environment) program [20].
The biological activities of all compounds were shown
in Table 1 along with its negative logarithmic units,
pIC50 values. Stereochemistry and atom typing wereconfirmed for each compound. Three different
charges i.e., GH, AM1BCC and MMFF94 were ap-
plied to the dataset and all three sets were subjected
to the database alignment by using sybyl7.3 [16]. The
database alignment is depicted in Figure 1. The core
structure of most active compound 32 (pIC50 =
12.10) was used as a template for alignment [21] in
ligand-based QSAR. On the other hand, for structure-
based QSAR, bound conformation of original com-
pound was used as template for alignment.CoMFA & CoMSIA 3D-QSAR models
The dataset of 102 compounds were segregated into
training and test sets containing 78 and 24 com-
pounds, respectively (Tables 1 and 2). Each set was
constructed on basis of regular distribution of bio-
logical activities (Table 1). Comparative Molecular
Field Analysis (CoMFA) and Comparative Molecular
Similarity Indices Analysis (CoMSIA) with 2Å grid
spacing, sp3 carbon probe atom with a charge of +1
and VdW radius of 1.52Å was used to calculate steric
and electrostatic field descriptors. In order to reduce
noise and improve efficiency, column filtering of 2.0
kcal mol-1 was used [16]. A default cutoff of 30 kcal
Ul-Haq et al. Chemistry Central Journal 2013, 7:88 Page 11 of 12
http://journal.chemistrycentral.com/content/7/1/88mol-1 was used for field energy calculations. Subse-
quently partial least square (PLS) analysis was
performed to obtain 3D-QSAR model.
The optimal number of components was determined
by leave-one-out procedure (Cross validation) to build
the statistical significant regression model. The quality
of the model was judged by cross-validated coefficient q2
which should not be less than 0.5. The external
predictivity was calculated by conventional correlation
coefficient r2 [22,23].
Molecular docking by GOLD
The dataset of 102 compounds was subjected to
docking in order to validate the QSAR results via
GOLD docking suit [12]. The emphasis was totally on
most active and the least active compounds to evalu-
ate their quality of interaction as HIV-1 protease in-
hibitors. For docking, wild type (PDB: 3EKV) [24],
and mutated I84V (PDB: 3NU9) [25] proteins were
retrieved from Protein Data Bank (PDB) [26] in order
to check the consistency of ligand’s interactions even
if mutated viral attack is present.
The cognate ligand and water molecules were re-
moved, and polar hydrogens were added. Software
was validated by re-docking and root mean square
deviation (RMSD) calculations shown in Table 5 and
Figure 5. Default GOLD docking parameters were
used with Gold-score and Chem-score as scoring and
rescoring functions. For each ligand, ten docked poses
were saved and analyzed.
Additional file
Additional file 1: Darunavir derivatives with all sibstitutions. Core
structure of darunavir with positions marked for substitutions and
structures of substituents at R1, R2 and R3 positions along with their
experimental inhibitory activities.
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